Clinical trials: Diabetes Mellitus (DM)
Type 2 Diabetes Mellitus
Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study)
To compare efficacy and safety of initial combination therapy of Gemigliptin versus Sitagliptin or Glimepiride with Metformin on Glucose Variability(MAGE, Glucose SD) in Patients With Type 2 Diabetes Mellitus.
- Trial name
- STABLE (NCT01890629)
- Testing
- Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin
- Where
- South Korea
- Volunteers
- 69 people
- Sponsor
- LG Life Sciences
Diabetes Mellitus, Non-Insulin-Dependent
The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus
The efficacy and safety study of saxagliptin 5mg, once daily for 24 weeks in patients with type 2 diabetes mellitus.
- Trial name
- SUNSHINE (NCT01608724)
- Testing
- Saxagliptin
- Where
- 37 sites in China
- Volunteers
- 2,165 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus (DM)
A Study of VCT220 Tablets in Adults With Type 2 Diabetes and Inadequate Blood Glucose Control
This study will evaluate whether VCT220 tablets improve blood glucose control in adults with type 2 diabetes whose blood glucose remains inadequately controlled with lifestyle intervention alone, metformin alone, or metformin…
- Trial name
- VICTOR-DM (NCT07872436)
- Testing
- VCT220 tablets
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Vincentage Pharma Co., Ltd
Type 2 Diabetes Mellitus (T2DM)
Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients
The purpose of this study was to assess the efficacy and safety of vildagliptin 50 mg bid add-on therapy to improve overall glycemic control in patients with T2DM inadequately controlled by insulin, with or without concomitant…
- Trial name
- NCT02002221
- Testing
- Vildagliptin (LAF237), Insulin, Metformin
- Where
- 31 sites in Japan
- Volunteers
- 156 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes (DM), Diabetes Mellitus Type 2
Bridge Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Patients With T2DM Inadequately Controlled by Diet and Exercise Alone
This Phase 3 Bridge study is designed to evaluate the efficacy and safety of IN-B00009 Injection in Patients with T2DM Inadequately Controlled by Diet and Exercise Alone
- Trial name
- NCT07308184
- Testing
- IN-B00009
- Volunteers
- 110 people
- Sponsor
- HK inno.N Corporation
Type 1 Diabetes, Type 1 Diabetes Mellitus
Evaluating Glucose Control Using a Next-Generation AID Algorithm in Individuals With T1D
Feasibility study to evaluate the safety and feasibility of Omnipod automated insulin delivery algorithms in individuals with type 1 diabetes.
- Conditions
- Type 1 Diabetes, Type 1 Diabetes Mellitus, Diabetes (DM)
- Trial name
- EVOLUTIONT1D (NCT07593625)
- Testing
- Omnipod M System, Omnipod S
- Where
- New Zealand
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Insulet Corporation
Type 2 Diabetes, Diabetes (DM)
Detecting Type 2 Diabetes From Voice
The goal of this observational study is to learn if computer analysis of voice recordings can detect Type 2 diabetes in adults. The main questions it aims to answer are: Can advanced voice analysis accurately identify…
- Conditions
- Type 2 Diabetes, Diabetes (DM), T2DM, T2DM (Type 2 Diabetes Mellitus)
- Trial name
- NCT07421921
- Where
- United Kingdom
- Volunteers
- 7,319 people, healthy volunteers welcome
- Sponsor
- Thymia Limited
RELATED REGISTRY SEARCH
HF Prevalence and Evolution of HF in DM II Patients at High Risk
This is an epidemiological, single-country, multicenter, 2-year prospective cohort study based on both primary and secondary data collection, which will include a representative sample of 300 eligible T2DM patients managed in…
- Trial name
- HF-LanDMark (NCT04482283)
- Where
- 10 sites in Greece
- Volunteers
- 245 people
- Sponsor
- AstraZeneca
Prediabetic
Efficacy and Safety of DLBS3233 in Prediabetic Patients
This is a 2-arm, prospective, double blind, randomized, and controlled clinical study for 12 weeks of therapy to investigate clinical efficacy and safety of DLBS3233.
- Trial name
- DIPPER-DM (NCT01531933)
- Testing
- DLBS3233
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- Dexa Medica Group
T2DM, Diabete Type 2
Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin
Phase 3 study to assess the Efficacy and Safety of CT-L02-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Alogliptin Combination Therapy.
- Conditions
- T2DM, Diabete Type 2, DM
- Trial name
- NCT07093476
- Testing
- Metformin, Alogliptin, empagliflozin
- Where
- South Korea
- Volunteers
- 171 people
- Sponsor
- Celltrion
Diabetes (DM)
Clinical and Home Use Feasibility Study of a Percutaneous Optical Glucose Fiber Sensor
This is a single-centre, open label (unblinded) prospective study investigating the performance and safety of FiberSense system in diabetic patients (Typ I and II).
- Trial name
- NCT04152408
- Testing
- FiberSense System
- Where
- Germany
- Volunteers
- 7 people
- Sponsor
- EyeSense GmbH
Diabetes Mellitus Type 2
ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus
The purpose of this study is to evaluate whether a combination of pharmacist-delivered patient engagement techniques improves disease control and medication adherence among patients with poorly-controlled diabetes compared with…
- Trial name
- ENGAGE-DM (NCT02910089)
- Testing
- Shared Decision Making
- Where
- United States
- Volunteers
- 1,400 people
- Sponsor
- AstraZeneca
Hypertension, Type 2 Diabetes Mellitus
A Comparison of Indapamide SR 1.5 mg With HCTZ 25 mg, in Combination With an ACE-inhibitor, in Patients With Mild to Moderate AHT and Type 2 DM
The aim of this study is to evaluate the effects of indapamide SR 1.5 mg on blood pressure, blood tests (glucose metabolism, lipids, minerals, and uric acid), cardiac function, endothelial and arterial function, by comparison…
- Trial name
- AISHA (NCT00980187)
- Testing
- Hydrochlorothiazide, Indapamide
- Where
- Romania
- Volunteers
- 56 people
- Sponsor
- LaborMed Pharma S.A.
Chronic Heart Failure, Type 2 Diabetes
Prognostic Impact of Diabetes and Weight Variability in Telemonitored Heart Failure
This observational cohort study evaluates the prognostic impact of diabetes, comorbidity burden, and short-term weight variability among adults with chronic heart failure enrolled in a nationwide remote patient monitoring program…
- Conditions
- Chronic Heart Failure, Type 2 Diabetes, Diabetes (DM)
- Trial name
- DM-HF-Tele (NCT07561866)
- Testing
- Diabetes Status, Comorbidity Burden, Weight variability
- Where
- France
- Volunteers
- 16,556 people
- Sponsor
- Satelia
Diabetes Mellitus, Type 2
Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition
Primary Objective: 1- Proportion of patients with mean daily glycemia <140mg/dL during the period of 7 days of treatment with glargine plus supplemental glulisine versus patients with glulisine sliding scale.
- Trial name
- NCT01081938
- Testing
- INSULIN GLARGINE, INSULIN GLULISINE
- Where
- 10 sites in Brazil
- Volunteers
- 15 people
- Sponsor
- Sanofi
Complications of Diabetes Mellitus, Diabetes Mellitus
Effect of Diacerein in the Metabolic Control of Patients With DM Type 2 and Secondary Failure to Metformin
Considering that, Diacerein is on the market for 16 years being used continuously in elderly patients with osteoarthritis without experience significant side effects, and considering the anti-hyperglycemic effect and the…
- Conditions
- Complications of Diabetes Mellitus, Diabetes Mellitus, Diabetes Mellitus, Type 2
- Trial name
- NCT03208309
- Testing
- Diacerein
- Where
- 3 sites in Brazil
- Volunteers
- 40 people
- Sponsor
- ANS Pharma
Diabetes Mellitus, Type 2
RF Vapor Ablation Retreatment of Duodenal Mucosa in Non-responders With Type-2 Diabetes Mellitus
The purpose of this study is to test the hypothesis that re-treatment of the duodenal mucosa with RF vapor ablation will result in improvement in glycemic parameters, without complications (bleeding/ stricture / perforation)…
- Trial name
- NCT06724822
- Testing
- RF Vapor Ablation
- Where
- Chile
- Volunteers
- 12 people
- Sponsor
- Aqua Medical, Inc.
Obesity
BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus
The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients with Type II diabetes mellitus treated with metformin, sulfonylurea (SFU)…
- Trial name
- NCT00603291
- Testing
- Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID)
- Where
- United States
- Volunteers
- 604 people
- Sponsor
- Eisai Inc.
Diabetes Mellitus, Non-Insulin-Dependent
Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)
After 24 weeks of treatment, to assess the A1C-lowering efficacy of sitagliptin 100 mg once daily added to the regimen of patients with inadequate glycemic control on metformin monotherapy
- Trial name
- NCT00875394
- Testing
- sitagliptin phosphate, Comparator: metformin, Comparator: Antidiabetic Standard of Care
- Volunteers
- 68 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Type 2, Diabetes
Study Evaluating the Metabolic Effects of pulsENDO Therapy in Adults With Type 2 Diabetes
This is a prospective, multicenter, randomized, double-blind, sham-controlled, adaptive study evaluating the pulsENDO system in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering…
- Conditions
- Diabetes Type 2, Diabetes, Diabetes (DM), Weight Change
- Trial name
- pulsENDO (NCT07768631)
- Testing
- pulsENDO Therapy
- Volunteers
- 320 people
- Sponsor
- Endogenex, Inc.